Succeed with Risk-sharing Agreements (RSAs)

Gain an overview of what you can achieve with risk sharing agreements in Denmark and EU

Date icon

30 May 2024

or

6 Nov 2024

Attendance icon

On location

Language icon

English

Price icon
6,000 DKK ex VAT

(app. 807 EUR ex VAT)

50% DISCOUNT FOR PUBLIC INSTITUTIONS

Summary

Is a different approach to pricing agreements between pharma and payers a viable path to faster market introduction of new, innovative medicine such as ATMP? What problems do we solve with outcome-based risk sharing agreements and what are the opportunities (and challenges) for patients, society, and the pharma industry?

Outcome-based risk sharing agreements (OBRSAs) are not a new phenomenon. Yet risk sharing pricing agreements are still quite rare, among other because of a high level of complexity and limited experiences to date.

The one day course is based on Danish market conditions and Danish data, but we will discuss use of risk sharing agreements (RSAs) in an international and global perspective. We also showcase the new possibilities for data access via European Health Data Space (EHDS).

You’ll leave this course with in-depth knowledge about risk sharing agreements both in Denmark and the EU. You’ll be familiar with specific agreement types and know how to assess when outcome-based (OBRSAs) risk sharing agreements are particularly effective both from a payer  and industry perspective. Last, but not least, you will be introduced to how to get started with RSAs.  

Keywords


Save information for later
Read more

Course leader & lecturers

  • Tove Holm-Larsen
    Course leader
    CEO
    Pharmaevidence
  • Trine Pilgaard
    Lecturer
    H&V Lead
    Pfizer ApS
  • Kenneth Forsstrøm Jensen
    Lecturer
    Strategic Market Access Manager
    Roche A/S
  • Henrik Ib Jørgensen
    Lecturer
    Direktør
    Muskelsvindfonden
  • Linda Thomsen
    Lecturer
    Head of Department, Rare Diseases
    Medicinrådet
  • Marie Gerstrøm Kristiansen
    Lecturer
    Head of Horizon Scanning and New Medicines
    Amgros I/S
  • Brian Holch Kristensen
    Lecturer
    Innovationschef
    Bispebjerg og Frederiksberg Hospital
See all

Is this course for you?

This course is relevant for you if you work with Market Access e.g. in ATMP, rare disease, or oncology in general and have some commercial experience.

What you will learn


  1. Understand the rationale behind outcome-based risk sharing agreements (OBRSAs).
  2. Understand how to put a price on risk in various constellations of public-private collaborations.
  3. Know where to find data evaluating outcome-based risk sharing agreements (OBRSAs) in Denmark and the EU.
  4. Understand the uncertainty experienced from both a payer perspective (the national healthcare system) and the industry’s perspective.

    What your company will get


    1. An employee who can bring new valuable knowledge about use of outcome-based risk sharing agreements (OBRSAs) back to the organization
    2. An employee who can develop a market access strategy based on use of OBRSAs
    3. An employee, who has a solid understanding of the uncertainty related to OBRSAs as seen from both Payer and industry side

      Course calendar

      Choose your starting date
      Starting 30 May 2024
      Starting 6 Nov 2024
      30 May 2024 9:00-16:00
      • What problem are we trying to solve with innovative pricing?
        • The patient perspective
        • The healthcare (= Payer) perspective
      • Market access in relation to rare diseases.
      • Various types of outcome-based pricing agreements (OBRSAs) applied in DK and EU.
      • Panel discussion: What do pharma companies think and do in regards to RSAs today? What have they learned?
      Practical information

      Registration

      Registration deadline
      16 May 2024
      Atrium
      Lersø Parkallé 101
      2100 København Ø
      Updated price: 6,500 DKK
      Register
      30 May
      6 Nov 2024 9:00-16:00
      • What problem are we trying to solve with innovative pricing?
        • The patient perspective
        • The healthcare (= Payer) perspective
      • Market access in relation to rare diseases.
      • Various types of outcome-based pricing agreements (OBRSAs) applied in DK and EU.
      • Panel discussion: What do pharma companies think and do in regards to RSAs today? What have they learned?
      Practical information

      Registration

      Registration deadline
      22 Oct 2024
      Atrium
      Lersø Parkallé 101
      2100 København Ø
      Register
      6 Nov
      Sometimes things change. This is the expected programme.

      Course information

      Literature

      Prior to the course you will get access to mandatory and optional readings via your personal Atrium log-in.

      Please familiarise yourself with mandatory readings before course start.

      Prerequisites

      Min. 3 years’ experience in Market Access, Medical Affairs, or a Commercial function in Pharma.

      Examination

      There is no examination for this course.

      This course is one of the elective courses, if you wish to take a Diploma in Market Access.

      This course is a part of a diploma

      Diploma in Market Access

      Our Diploma in Market Access provides you with in-depth knowledge of the Danish healthcare system and its funding models and stakeholders. Raise your skill level in areas such as public affairs, stakeholder management and health economics by attending the four courses

      Read more

      Course leader

      Tove Holm-Larsen
      CEO
      Pharmaevidence

      Lecturers

      Trine Pilgaard
      H&V Lead
      Pfizer ApS
      Tove Holm-Larsen
      CEO
      Pharmaevidence
      Kenneth Forsstrøm Jensen
      Strategic Market Access Manager
      Roche A/S
      Henrik Ib Jørgensen
      Direktør
      Muskelsvindfonden
      Linda Thomsen
      Head of Department, Rare Diseases
      Medicinrådet
      Marie Gerstrøm Kristiansen
      Head of Horizon Scanning and New Medicines
      Amgros I/S
      Brian Holch Kristensen
      Innovationschef
      Bispebjerg og Frederiksberg Hospital

      You may also be interested in these courses

      Want to know more, or need help?

      Contact Client Manager Ida Salicath at +45 39 15 09 46

      Send me an email